NNZ-2566 has certainly ticked a lot of boxes including the boxes identified by Virani. The 'potential for new opportunities beyond initial applications' is particularly valid noting your 'pipeline within a drug' assessment.
It sure has Wayne.
This comment from Virani also stood out out for me.
"There's a big focus for innovation".
Neuren certainly have a product in development that is unique or genuinely novel based on the target, mechanism, therapeutic focus, indication, etc. and that is truly disruptive to established product positions. Pharma know this and yes agree, 2013 could definitely be the year that Neuren goes global. Looking forward to it.
NEU Price at posting:
3.5¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)